Zentalis Pharmaceuticals Llc - Asset Resilience Ratio
Zentalis Pharmaceuticals Llc (ZNTL) has an Asset Resilience Ratio of 72.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Zentalis Pharmaceuticals Llc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Zentalis Pharmaceuticals Llc's Asset Resilience Ratio has changed over time. See Zentalis Pharmaceuticals Llc net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zentalis Pharmaceuticals Llc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zentalis Pharmaceuticals Llc (ZNTL) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $209.90 Million | 72.64% |
| Total Liquid Assets | $209.90 Million | 72.64% |
Asset Resilience Insights
- Very High Liquidity: Zentalis Pharmaceuticals Llc maintains exceptional liquid asset reserves at 72.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zentalis Pharmaceuticals Llc Industry Peers by Asset Resilience Ratio
Compare Zentalis Pharmaceuticals Llc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Zentalis Pharmaceuticals Llc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Zentalis Pharmaceuticals Llc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 72.64% | $209.90 Million | $288.97 Million | -5.72pp |
| 2024-12-31 | 78.35% | $337.18 Million | $430.34 Million | -2.58pp |
| 2023-12-31 | 80.94% | $454.88 Million | $562.03 Million | +9.69pp |
| 2022-12-31 | 71.24% | $394.30 Million | $553.46 Million | +11.89pp |
| 2021-12-31 | 59.36% | $280.17 Million | $472.02 Million | -18.21pp |
| 2020-12-31 | 77.57% | $283.55 Million | $365.56 Million | -- |
About Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosert… Read more